Effects of gender-affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons by Defreyne, Justine et al.
Effects of Gender-Afﬁrming Hormones on Lipid,
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Transgender Persons
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and Guy G.R. T’Sjoen1,4
BACKGROUND: Gender-affirming hormonal therapy con-
sists of testosterone in transgendermen and estrogens and
antiandrogens in transgender women. Research has con-
cluded that gender-affirming therapy generally leads to
high satisfaction rates, increased quality of life, and
higher psychological well-being. However, given the
higher incidence of cardiometabolic morbidity and mor-
tality in cisgender men compared with cisgender women,
concerns about the cardiometabolic risk of androgen
therapy have been raised.
CONTENT: A literature research was conducted on Pub-
Med, Embase, and Scopus, searching for relevant articles
on the effects of gender-affirming hormone therapy on
cardiometabolic risk and thrombosis. After screening 734
abstracts, 77 full text articles were retained, of which 11
were review articles.
SUMMARY: Studies describing a higher risk for cardio-
metabolic and thromboembolic morbidity and/or mor-
tality in transgender women (but not transgender men)
mainly covered data on transgender women using the
now obsolete ethinyl estradiol and, therefore, are no lon-
ger valid. Currently, most of the available literature on
transgender people adhering to standard treatment regi-
mens consists of retrospective cohort studies of insuffi-
cient follow-up duration. When assessing markers of
cardiometabolic disease, the available literature is incon-
clusive, which may be ascribed to relatively short
follow-up duration and small sample size. The impor-
tance of ongoing large-scale prospective studies/registries
and of optimal management of conventional risk factors
cannot be overemphasized.
© 2018 American Association for Clinical Chemistry
Transgender people are persons whose gender identity
differs from their birth-assigned sex. When associated
with distress or impairment in social, educational, or
other important areas of functioning, gender dysphoria
may occur. Although this review focuses mainly on fem-
inizing and masculinizing gender-affirming hormone
therapy (HT)5, “transgender” is an umbrella term refer-
ring to a spectrum of gender identities and may include
people living with gender incongruence and not search-
ing a transition, those making a social transition only
without medical needs, and/or gender-nonconforming
persons. These subgroups are often not included in stud-
ies and, therefore, are underrepresented in the current
review. Population-based questionnaire-generated esti-
mates for the prevalence of gender incongruence range
from 0.5% to 1.3% for birth-assigned males and 0.4% to
1.2% for birth-assigned females (1 ).
The number of transgender persons seeking gender-
affirming care is increasing (2 ), although access to health-
care remains precarious (3 ). Because of stigma and fear of
medicalization, transgender persons may encounter bar-
riers when accessing healthcare (4 ). Transgender care is
currently not a strong part of the medical curriculum (5 ),
which may lead to miscommunication, misinformation,
not referring trans persons to the appropriate care pro-
viders, postponing necessary healthcare, uncontrolled
hormone use, and self-performed gender-affirming sur-
gery (6 ). Therefore, it is important for healthcare workers
in both specialty and primary care to get acquainted with
1 Department of Endocrinology, Ghent University Hospital, Ghent, Belgium; 2 Depart-
ment of Internal Medicine, Ghent University Hospital, Ghent, Belgium; 3 Department of
Cardiology, Ghent University Hospital and Ghent University, Ghent, Belgium; 4 Center
for Sexology and Gender, Ghent University Hospital, Ghent, Belgium.
* Address correspondence to this author at: Department of Endocrinology, De Pintelaan
185, 9000 Ghent, Belgium. E-mail justine.defreyne@ugent.be.
† J. Defreyne and L.D.L. Van de Bruaene contributed equally.
Received August 2, 2018; accepted November 5, 2018.
DOI: 10.1373/clinchem.2018.288241
© 2018 American Association for Clinical Chemistry
5 Nonstandard abbreviations: HT, hormonal therapy; TW, transgender women; EE, ethinyl
estradiol; VTE, venous thromboembolism; CVD, cardiovascular disease; EV, estradiol val-
erate; GnRH, gonadotropin-releasing hormone agonist; TM, transgender men; PCOS,
polycystic ovary syndrome; T2DM, type 2 diabetes mellitus; HRT, hormone replacement
therapy; RR, relative risk; CEE, conjugated equine estrogen; BMI, body mass index;
WHR, waist– hip ratio; aPTT, activated partial thromboplastin time; PTT, partial thrombo-
plastin time; PT, prothrombin time; INR, international normalized ratio; aHR, adjusted
hazard ratio; TIA, transient ischemic attack; SIR, standardized incidence ratio; DVT, deep
venous thrombosis.
Clinical Chemistry 65:1
119–134 (2019) Reviews
119
D
ow
nloaded from
 https://academ
ic.oup.com
/clinchem
/article-abstract/65/1/119/5607900 by G
hent U
niversity user on 09 M
arch 2020
the needs of transgender persons and to understand the
impact on morbidity and mortality.
Gender-Afﬁrming HT
In transgender women (TW), gender-affirming HT con-
sists of estrogens and antiandrogen agents. Before 2003,
the main estrogen agent used in the US was conjugated
equine estradiol, whereas in Europe, ethinyl estradiol
(EE) was more frequently prescribed to TW. However,
epidemiological studies revealed an increased risk for ve-
nous thromboembolism (VTE) and cardiovascular dis-
ease (CVD) (7 ), which has led to most clinics abandon-
ing EE for oral [estradiol valerate (EV)], cutaneous
(estradiol patches or estradiol gel), or intramuscular 17-
estradiol (EV or cypionate) aimed at cisgender female
reference ranges (8 ). Antiandrogen therapy [spironolac-
tone, cyproterone acetate, or gonadotropin-releasing
hormone (GnRH) agonists] is usually added to reduce
endogenous testosterone concentrations to concentra-
tions found in cisgender women (8 ).
In transgender men (TM), HT consists of testoster-
one, aimed at inducing virilization. Available formula-
tions depend on geographical region. Most commonly
prescribed are parenteral testosterone cypionate, enan-
thate, or esters (both intramuscularly and subcutane-
ously) or long-acting testosterone undecanoate (8 ).
Other options include testosterone gel or transdermal
patches. If cessation of menstrual bleeding is desired, a
progestational agent can be added to the treatment in
case amenorrhea did not occur upon initiation of testos-
terone therapy (9 ). HT is currently continued lifelong to
maintain virilization/feminization and avoid symptoms
of hypogonadism. The recommended dose of different
treatment modalities can be found in the Endocrine
Society guideline Endocrine Treatment of Gender-
Dysphoric/Gender-Incongruent Persons: An Endocrine
Society Clinical Practice Guideline (8 ).
Sex Hormones and Cardiovascular Risk
In general, CVD occurs 10 years earlier in men (10 ).
Besides higher blood pressures and (historically) more
prevalent smoking, this difference may additionally be
caused by sex hormone differences, as testosterone may
affect cardiovascular risk, inducing increasing lipid
atherogenicity, a more unfavorable body fat distribution,
increased insulin resistance, and increasing total homo-
cysteine concentrations (11, 12 ). In contrast, estrogens
increase thrombotic risk in women through procoagulant
shifts in the hemostatic system (increased factors II, VII,
VIII, X and fibrinogen levels; decreased antithrombin
and protein S levels). Estrogens are also associated with
development of activated protein C resistance (13 ).
Testosterone has androgenic and anabolic effects;
stimulating protein synthesis and fat oxidation and re-
ducing lipid storage (14 ). Low testosterone concentra-
tions in cisgender men may lead to frailty, bone loss,
atherosclerosis progression, coronary artery disease, dia-
stolic cardiac dysfunction, adverse metabolic phenotype,
and overall increased cardiovascular morbidity and mor-
tality (15–21), whereas high testosterone concentrations
in cisgender women with polycystic ovary syndrome
(PCOS) are associated with higher cardiovascular and
metabolic risk (21, 22 ). Visceral fat is associated with
insulin resistance syndrome in both sexes; men and post-
menopausal women tend to store fat predominantly in
the abdominal area, premenopausal women store fat
mainly in subcutaneous depots on hips and thighs (23 ).
Visceral fat accumulation is a risk factor for CVD and
type 2 diabetes mellitus (T2DM) (24 ). In women with
increased androgen levels and postmenopausal women
with decreased estradiol concentrations, visceral fat is in-
creased compared with controls (23, 25 ). In men, estra-
diol concentrations are positively related to subcutaneous
abdominal but not visceral fat owing to decreased aroma-
tase activity in visceral compared with gluteal fat (26 ).
Low testosterone concentrations in men are associated
with visceral obesity (27 ).
Observational studies reported increased risk of
VTE, stroke, and myocardial infarction in premeno-
pausal women using oral contraceptives (13, 28 ) and
higher thrombosis rates in men with prostate cancer
treated with GnRH agonists, bilateral orchiectomy, or
high-dose estrogens (29, 30 ).
Renoux et al. (31 ) metaanalyzed the literature on
VTE risk in menopausal cisgender women prescribed
hormone replacement therapy (HRT) and described a
higher VTE risk associated with oral estrogen-only ther-
apy [relative risk (RR), 1.49; 95% CI, 1.37–1.63] and
oral estrogen plus progestogen therapy (RR 1.54; 95%
CI, 1.44–1.65), but not with transdermal estrogen use
alone or in combination with a progestogen. Observa-
tional studies and randomized controlled trials of cardio-
vascular risk in cisgender women taking HRT appear to
have divergent results, with some studies (32, 33 ) report-
ing increased risk for CVD and myocardial infarction
in postmenopausal women prescribed an estrogen–
progestogen HRT combination, some studies reporting
no impact of midterm (5 years) oral estrogen plus pro-
gestogen HRT on cardiovascular mortality (34 ), and
other studies reporting decreased risk for CVD in cisgen-
der women given HRT (35 ). These differences may be
related to age, time since menopause, and HRT formu-
lation (36 ). Available literature on HRT and CVD was
metaanalyzed in 2015 by Benkhadra et al. (37 ), who
reported no association between HRT and cardiac or
strokemortality, independent of HRT regimen (estrogen
only vs estrogen and progestogen therapy). However, as
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HRT frequently consists of low-dose oral conjugated
equine estrogens (CEEs) with or without medroxypro-
gesterone acetate, research on HRT in menopausal
women may not be comparable with that in TW, who
use higher doses of 17- estradiol combined with
antiandrogens.
Plasma lipid concentrations are differently distrib-
uted in adult (not infant) men and women, with a higher
HDL/LDL ratio in women. Administration of andro-
gens to (hypogonadal) men and women results in de-
creased HDL concentrations, independent of estradiol
concentrations (38, 39 ).
Arterial compliance and distensibility are necessary
to convert pulsatile flow to steady perfusion flow to the
organs. Arterial stiffening increases cardiac afterload and
systolic blood pressure, which contributes to CVD (40 ).
Estrogen receptors are expressed in vascular endothelial
and smooth muscle cells (41, 42 ), and estrogen therapy
has been associated with improved arterial function (43 ).
However, both the Framingham Heart Study (44 ) and
Collaboration for Reference Values for Arterial Stiffness
(45 ) report no correlation between sex and carotid–
femoral pulse wave velocity, the most robustly studied
marker for arterial stiffening.
Previous research reported a beneficial effect of HT
on surrogate cardiovascular risk markers (e.g., lipids,
body composition, insulin metabolism, heart rate, blood
pressure) in TW and disadvantageous effects in TM
(46, 47 ). There have been concerns about long-term ef-
fects of HT on cardiovascular outcomes, although large
prospective trials of sufficient duration have not been
reported in transgender persons.
Methods
This systematic review [in accordance with PRISMA
guidelines (48 )] was performed using PubMed, Scopus,
and Embase, from February 15 until June 1, 2018. We
searched for cardiovascular and thromboembolic risk fac-
tors, as well as events. The following cardiovascular risk
factors were considered biologically modifiable and po-
tentially affected by HT: dyslipidemia (total cholesterol,
LDL, HDL, and triglycerides), insulin sensitivity (im-
paired fasting glucose, insulin resistance, metabolic syn-
drome, and T2DM), arterial blood pressure (systolic, di-
astolic, mean), arterial stiffness, body mass index (BMI),
and waist–hip ratio (WHR). We included the following
thromboembolic risk factors: serum hematocrit levels,
hemoglobin levels, clotting factors, fibrinogen, (acti-
vated) partial thromboplastin time (aPTT, PTT), pro-
thrombin time (PT), and its international normalized
ratio (INR).
An overview of our search strategy can be found in
the Data Supplement that accompanies the online ver-
sion of this article at http://www.clinchem.org/content/
vol65/issue1. Only cohort studies, cross-sectional stud-
ies, and randomized controlled trials were included.
Previous review articles and metaanalyses were not in-
cluded in the tables. Two investigators (JD and LVDB)
independently reviewed 734 abstracts, of which 77 were
retained, which contained 11 review articles. Addition-
ally, 2 manuscripts were added between first and final
submission. Only English-language articles including
transgender people taking HT were considered eligible.
Articles were assessed based on the GRADE tool by JD
and LVDB independently.
Results
This review includes 4 original studies on cardiovascular
mortality (Table 1), 12 on cardiovascular morbidity (Ta-
ble 1), 12 on blood pressure (Table 2), 25 on lipids (Sup-
plemental Table 1), 24 on body composition (Supple-
mental Table 2), and 19 on markers of increased
thrombosis (Supplemental Table 3).
CARDIOVASCULAR MORTALITY
Currently, there are no long-term prospective follow-up
studies available with a substantial cohort size to assess
mortality risk in transgender people, only retrospective
cohort studies (Table 1, Mortality section). Earlier re-
views of the literature concluded that the level of evidence
was too low to allow an interpretation of morbidity and
mortality risk in transgender people (47, 49, 50 ). Several
retrospective cohort studies (7, 51 ) reported increased
mortality in TW, mainly attributable to suicides (7, 51 )
and not hormone-related causes. Other retrospective co-
hort studies (52, 53 ) reported no increased mortality
over 4.4 years, or 10152 patient-years, of follow-up. Ass-
cheman et al. (7 ) reported a higher number of cardiovas-
cular deaths in TW than expected based on population
prevalences, over 19.3 years of follow-up in a retrospec-
tive cohort study. Dhejne et al. (51 ) reported an adjusted
hazard ratio (aHR) of 2.5 in transgender people (no sub-
stratification) compared with a Swedish control popula-
tion. Asscheman et al. (7 ) observed an increased stan-
dardized mortality rate for ischemic heart disease [1.64
(95% CI, 1.43–1.87)] but not fatal stroke [2.11 (95%
CI, 0.93–1.64)] in TW. Most cardiovascular deaths oc-
curred in current or former smokers. Use of EE was as-
sociated with cardiovascular mortality but not with in-
creased risk of all-cause mortality. However, we must
acknowledge that the cited literature here is exclusively
European.
CARDIOVASCULAR MORBIDITY
In absence of evidence that HT according to current
treatment regimens leads to increasedmortality, assessing
morbidity is equally important (Table 1, Morbidity sec-
tion). A recent metaanalysis reported no increased risk of
Trans People: Cardiometabolic/Thromboembolic Risk Reviews
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myocardial infarction, stroke, or VTE in transgender
people, probably because of lack of reported outcomes
from eligible studies (47 ). Two cross-sectional studies
(54, 55 ) reported increased prevalence of myocardial in-
farction in TW taking HT compared with an age-
matched group of cisgender women but not compared
with cisgender men.
Three large retrospective cohort studies (51, 54, 56 )
reported increased myocardial infarction and cerebrovas-
cular disease rates in TW prescribed HT compared with
cisgender people. However, only the study byWierckx et
al. (54 ) provided elaborate information on type of
gender-affirming HT (which included EE). Getahun et
al. (56 ) reported an increased incidence of acute myocar-
dial infarction in TW compared with cisgender women
but not compared with cisgender men. A population-
based survey in the US reported higher myocardial in-
farction odds in TW compared with cisgender women
but not compared with cisgender men. The risk for car-
diovascular events was comparable with the general pop-
ulation for TM and gender-nonconforming people.
However, they did not specify how many transgender
people were taking HT (55 ). Another large retrospective
cohort (52 ) reported a possible reduction in myocardial
infarction-related morbidity in TW compared with cis-
gender men.
STROKE
Stroke and/or transient ischemic attack (TIA) have been
described in TW (53, 57, 58 ), although studies that
computed RRs or aHRs are scarce (52, 54–56). The
cross-sectional study by Wierckx et al. (54 ) showed a
higher prevalence of TIA/CVD in TW (23.4 cases/1000
persons) compared with cisgender men (9.4 cases/1000
persons) but not compared with cisgender women. A
more recent study by Getahun et al. (56 ) reported an
increased incidence of stroke in TW compared with cis-
gender women [aHR, 1.8 (95% CI, 1.1–2.9)] but not
compared with cisgender men [aHR, 1.2 (95% CI, 0.9–
1.7)]. However, Getahun et al. (56 ) did not provide de-
tailed information on type of estrogen used by the TW in
their study. These results are contradicted by 2 older large
retrospective cohort studies (52, 53 ) and 1 recent (2018)
cross-sectional study. Asscheman et al. (53 ) reported no
increased risk for TIA in TW (statistics not available).
Van Kesteren et al. (52 ) reported a standardized inci-
dence ratio (SIR) of 1.71 (95% CI, 0.63–3.88) in TW
compared with the National Civil Record Registry. The
population-based cross-sectional study by Nokoff et al.
(55 ) reported no increased stroke incidence compared
with control cisgender men and women.
Getahun et al. (56 ) reported a higher aHR for stroke
in TM [2.1 (95%CI, 1.3–3.5)] compared with cisgender
men [1.1 (95% CI, 0.6–2.0)] and cisgender women [1.3
(95% CI, 0.7–2.5)]. On the other hand, Nokoff et al.
(55 ) showed no increased stroke incidence in TM
compared with control cisgender men and women.
Maraka et al. (47 ) recentlymetaanalyzed the literature on
cardiovascular risk. Of the 340 individuals taking testos-
terone therapy included in the metaanalysis, no cases of
stroke were reported.
ARTERIAL HYPERTENSION
One review article (50 ) reported sodium and water
retention in 1.7% of TM (resolved after testosterone
dose reduction). Increased blood pressure was docu-
mented in 4.1%, comparable with prevalence studies
in healthy population-based samples (22 ). A large ret-
rospective study (52 ) observed only 3 cases of hyper-
tension in TM and 14 in TW, with an SIR of 0.34 for
TW (not calculated in TM), indicating no increased
risk for hypertension.
VTE
Given the prothrombotic actions of estrogens, increased
thrombosis risk is theoretically expected in TW (59 ).
However, increased VTE risk is predominantly docu-
mented in older studies reporting on TW prescribed EE.
Results on VTE risk in TW were previously reviewed by
Shatzel et al. (60 ), who reported a higher rate of VTE
with certain estrogens. The rate is highest with oral estro-
gen therapy, particularly EE, and lowest with transder-
mal estrogen and EV. Most cases of thrombosis occurred
in the first year after starting estrogen therapy and in TW
who smoked. One older retrospective study (52 ) re-
ported a 20-fold increase in VTE complications in TW
compared with cisgender women. Wierckx et al. (58 )
reported VTE in 1 TW (n 1, 2.0%), whereas none of
the (non–age-matched) TM (0%) experienced deep ve-
nous thrombosis (DVT). Seal et al. (61 ) reported in-
creased VTE risk in TW taking oral CEEs (4.4%) com-
pared with TW prescribed oral EV or EE (1.0%). In a
large retrospective cohort study (52 ), all but 1 TW who
experienced VTE were prescribed EE, and most adverse
events occurred within the first year of HT. VTE risk did
not increase with age. Getahun et al. (56 ) reported a 5.5
adjusted RR for VTE compared with cisgender peers.
However, information on type of oral estradiol was not
published. A recent study (62 ) reported VTE in 1 TW
after 2 years of taking estradiol (4 mg/day) and spirono-
lactone (200 mg/day), resulting in 0.15% VTE rate with
mean follow-up duration of 1.9 years.
T2DM
Although Nokoff et al. (55) reported no increased odds for
diabetes in transgender compared with cisgender adults,
Wierckx et al. (54) reported a higher prevalence of T2DM
comparedwith cisgender controls, with almost all diagnoses
made before starting HT in TW. However, results may be
biased by endocrine screening before initiating HT.
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MARKERS OF CARDIOVASCULAR AND METABOLIC MORBIDITY
Markers of cardiovascular and metabolic morbidity were
grouped in longer term (e.g., altered blood pressure, lip-
ids, increased insulin resistance) and short-term changes
(thrombosis).
Arterial blood pressure. The available research on the im-
pact of HT on systolic/arterial blood pressure showed
conflicting results in cross-sectional and prospective
studies (Table 2).
Two cross-sectional studies report conflicting results
(58, 63 ); Wierckx et al. (58 ) reported higher mean arte-
rial and diastolic (but not systolic) blood pressure in non–
age-matched TW taking HT compared with TM pre-
scribed HT, whereas Emi et al. (63 ) reported higher
systolic, mean arterial, and diastolic blood pressure in
TM given HT compared with TM not taking HT.
In prospective studies of transgender adults (64–
66), mean arterial, systolic, and diastolic blood pressure
increased or remained stable in TM, whereas it decreased
or remained stable in TW. This could not be explained
by studies on arterial stiffness (63, 67–69).
Lipids. Results regarding the impact of testosterone ther-
apy on lipid levels are often conflicting (Supplemental
Table 1). Most available studies report an increase in
HDL concentrations and a decrease in LDL in TW, and
a decrease in HDL concentrations in TM (64, 66, 69–
82). The impact of HT on LDL in TM is inconclusive
(65, 66, 78, 81, 83 ). Multiple studies report no change
in triglyceride concentrations in transgender people
(63–66, 70–75, 77, 79–81, 83–87).
However, the mechanism behind the observed
changes in plasma lipid levels after administration of HT
remains unknown, and it is unsure whether this will af-
fect cardiovascular risk, as several large cardiovascular
outcome trials concluded that HDL-altering treatment
did not affect cardiovascular outcome (88, 89 ). It ap-
pears thatHDLmetabolism rather than circulatingHDL
concentrations determines atherogenicity (38 ). Studies in
transgender people are again inconclusive (70, 75). Given
the small numbers of studies assessing lipid metabolism in
transgender people, we cannot unequivocally link HT to
atherosclerotic risk. Prospective studies with sufficient sam-
ple size, adhering to currently advised treatment regimens
and assessing both lipid concentrations andmetabolism, are
necessary to assess atherosclerotic risk.
Markers of insulin resistance. Insulin resistance has been
described in cisgender men with hypogonadism (90 ) and
in cisgender women with PCOS (91 ); thus, one would
expect increased insulin resistance in TM receiving tes-
tosterone and in TW receiving testosterone blockers. The
current literature covering transgender people provides
no uniform evidence of increased insulin resistance in
transgender people taking HT (57, 63, 64, 71, 72, 79–
81) (Supplemental Table 2), although other markers of
insulin sensitivity decreased during the first months of
testosterone therapy in TM compared with baseline (87 )
or compared with cisgender male reference ranges (92 ).
These results are contradicted in the randomized con-
trolled trial by Pelusi et al. (73 ), in which higher fasting
glucose concentrations were reported in TM after 12
months of HT, independent of type of testosterone. It
remains to be determined whether this will result in in-
sulin resistance. However, supraphysiological doses of
testosterone may induce insulin resistance in TM and
cisgender women (75, 93 ). Five prospective studies
(64, 72, 74, 75, 81 ) observed no change in fasting glu-
cose concentrations in TW, whereas 2 studies (74, 75 )
observed an increase in insulin resistance markers. How-
ever, the available prospective studies on insulin resis-
tance and metabolic risk in transgender people mainly
report on short-term data, and it remains unsure whether
the administration of testosterone may have effects on
insulin sensitivity, as this has not been described in longer
term studies.
Body composition. In general, most of the studies describe
a status quo or increase in BMI in transgender people
(66, 72, 75–77, 80–82, 94–97), although transgender
people taking HT are not more likely to be obese com-
pared with cisgender age-matched controls (54, 63, 94 )
(Supplemental Table 2). WHR tends to change toward
the desired gender (81, 98 ), which is also reflected in a
decrease in subcutaneous fat area and an increase in vis-
ceral fat in TM (75, 76, 98, 99 ) and an increase in sub-
cutaneous fat in TW (75, 76, 98 ) after initiation of HT.
However, an increase in visceral fat has been described in
TW (75, 98 ), probably because of decreased aromatase
activity in visceral fat in birth-assigned males compared
with birth-assigned females (26 ). Visceral fat is a strong
correlate of metabolic risk factors (100 ). It remains to be
determined whether the increase in visceral fat in trans-
gender people will result in higher cardiometabolic mor-
bidity in the longer term.
Markers of increased thrombotic risk. Several studies
describe an increase in hemoglobin and hematocrit
levels in TM during the first year of HT, with the
most pronounced increase during the first 3 months
(11, 12, 20, 63– 66, 71, 73, 74, 78, 83, 101–103 )
(Supplemental Table 3). Hematocrit levels remain stable
after the first year of HT (11, 12, 83, 101, 102). Although
testosterone therapy may induce erythrocytosis, clinically
significant erythrocytosis is rare (78, 81, 83, 101, 102). In
addition, testosterone therapy is also associated with an
increase in hemoglobin and hematocrit levels toward cis-
gender male reference ranges, with no clinically signifi-
cant erythrocytosis and no increased risk for VTE
(11, 12, 20, 63–66, 71, 73, 74, 78, 81, 83, 101–103).
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Several studies attempted to unravel the effects of sex
steroids on the coagulation pathway (Supplemental Ta-
ble 3). HT does alter elements of the coagulation path-
way, which may theoretically lead to increased thrombo-
sis risk in TM (86, 104–106) and TW (86 ), as well as
decreased thrombosis risk in TM (107 ) and TW (105 ).
The observed changes did not result in changes in coag-
ulation parameters (PT, aPTT, thrombin time, and fi-
brinogen concentration) in TM (77 ) and TW (86 ) 6 to
12 months after the initiation of HT. These studies are
limited by small cohort sizes.
Discussion
Given the relatively short follow-up duration in studies
assessing cardiovascular mortality and morbidity and
older studies reporting on TW using EE, it is possible
that effects of HT on cardiovascular mortality/morbidity
(if any) will become apparent only after long-term HT.
Assessing markers of CVD may give an idea about car-
diovascular, metabolic, and thromboembolic risk in
transgender people prescribed HT. However, the avail-
able literature remains inconclusive on this topic. It is
also possible that differences in type of gender-affirming
HT are (partially) responsible for conflicting results
among different studies. To date, there are no random-
ized controlled clinical trials available reporting on car-
diovascular mortality, morbidity, and/or risk among dif-
ferent HT formulations/doses.
The available literature does not suggest increased
risk for arterial hypertension, dyslipidemia, or insulin re-
sistance in TM, despite some markers of cardiovascular
and metabolic disease suggesting increased cardiometa-
bolic risk in TM (increasing WHR, increasing percent-
age of visceral fat, increasing/stable blood pressure and
BMI, and inconclusive effects on LDL) and in TW (in-
creasing percentage of visceral fat, increasing/stable
BMI). In contrast, other markers suggest a decreased risk
in TW (stable insulin resistance, decreasing/stable blood
pressure, and decreasing LDL andWHR). However, ab-
sence of proof is not proof of absence; in this regard, the
importance of ongoing large-scale prospective studies/
registries and of optimal management of conventional
risk factors (e.g., weight, LDL cholesterol, blood pres-
sure, smoking) as applicable to all cannot be overempha-
sized. Some conflicting results can be explained by the
older mean age of TW compared with TM, geographical
location, HT regimen, minority stress, or lifestyle factors.
Transgender people are more likely to smoke (108 ), con-
sume more alcohol (109 ), and have a lower level of phys-
ical activity (110 ) compared with cisgender population
references, and Vilas et al. (111 ) observed a mean daily
nutrient intake of 3614.3  1314 kcal. In addition,
transgender people often report feelings of discrimina-
tion resulting from transgender status (minority stress)
(112–114), which may be associated with increased
stress, health risk behavior, and long-term poor health
outcomes (115 ).
Based on available evidence, no increased risk for
cardiovascular mortality and morbidity is seen, when ad-
hering to recent treatment regimens. However, the avail-
able literature is currently inadequately powered to detect
this lack of difference. We must acknowledge the fact
that our data are limited by a relatively short follow-up
duration, without data on older transgender people
(46, 47, 52 ).More, large prospective cohort studies such as
the ongoing STRONG (116), ENIGI (117), and GETS
(118) studies are needed, which should include people of
different age categories and take confounding factors (e.g.,
lipid levels/metabolism, physical activity, body composi-
tion, dietary intake, mental well-being) into account. Also,
addition of the sociodemographic marker “gender identity”
to national health registries may help assess the risk for car-
diovascular and metabolic morbidities in transgender peo-
ple and may contribute to research on gender nonbinary
people, who are frequently ignored in the available litera-
ture. This will result in large databases, enabling faster de-
tection of subtle changes in cardiometabolic risk factors,
morbidity, and/ormortality.However,wemust also keep in
mind that there is sustainable evidence thatHTdecreases or
even resolves feelings of gender dysphoria in transgender
persons and ameliorates quality of life (96, 119–122),
whereas the available literature on cardiovascular mortality
andmorbidity in transgender people is limited in its level of
evidence.
The Endocrine Society guideline (8 ) suggests mon-
itoring weight, blood pressure, and lipids at regular inter-
vals. Without clear evidence of increased risk, absolute
cardiovascular risk calculation should be performed ac-
cording to local guidelines for the general population
before the initiation of gender-affirming hormones and
during follow-up. In addition, because emotional stress
can be as detrimental to cardiovascular health as physical
stress (123 ), we recommend addressing psychological
well-being and, if necessary, referral to a mental health
professional. As it is unclear which reference intervals are
more relevant for transgender individuals, risk calculation
using calculator settings for birth-assigned males (for safety
measures, these are more cautious compared with settings
for birth-assigned females) provides a sensitive estimate of
risk for TM and TW, but may lack specificity. If cardiovas-
cular risk factors emerge, they should bemanaged according
to established population-based guidelines.
In conclusion, although the currently available liter-
ature lacks power and is at moderate risk for bias, most of
the studies reported no increase in cardiovascular mor-
bidity for transgender people taking HT in short to me-
dium (10 years) follow-up periods. Known biochemical
markers of CVD show conflicting results for transgender
people prescribed HT. The degree to which CVD is at-
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tributable to traditional risk factors rather than sex ste-
roids themselves remains uncertain.
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